“2030 drug and gene delivery devices market value to reach USD 1.22 billion”
The global drug and gene delivery devices market size was valued at USD 670.0 million in 2023 and is projected to grow at a CAGR of 9.0% from 2024 to 2030. The increasing prevalence of chronic diseases such as diabetes, cancer, heart diseases, & other chronic disorders and technological advancements in drug and gene therapy has propelled the market growth.
The increasing adoption of the gene therapy and development in drugs due to the growing awareness about the availability of novel drugs, capable of curing chronic diseases has propelled the drug and gene delivery devices demand. The rising investments in research and developments of the new drug and cell therapy for treating the chronic diseases is among the key drivers contributing to the drug and gene delivery system market growth.
As various chronic diseases continue to spread globally, organizations have largely managed to develop multiple methods of drug delivery to achieve the best possible response. Targeted drug delivery enables doctors to focus specifically on the affected area of the body, thus avoiding potential side effects in surrounding areas. This approach not only prevents adverse effects but also ensures that the medicine remains effective at the intended site.
The market for drug and gene delivery devices is projected to increase as there is a rise in need for injectable medications. The global market for these devices has witnessed growth due to the rising number of chronic diseases such as cancer, diabetes, and cardiovascular diseases, as well as advancements in drug delivery methods. Moreover, leading companies in genomics are ramping up their research and development efforts. The expansion of the market is being driven by changing preferences of patients and healthcare providers towards these devices.
In 2023, the oral segment dominated the market and accounted for largest revenue share of 52.7%, owing to its convenience and ease of administration. Another reason in surge of oral segment is most of the drugs and medicines are available in tablet, liquid or powder form, which are generally administered through the oral route as patients are more comfortable with oral medications.
The injectable segment is expected to witness the fastest CAGR of 11.0% during the forecast period, fueled by increasing prevalence of life-threating diseases and advancement in injectable drug delivery devices. Moreover, the injectable devices provide faster relief as it enables the delivery of drugs to target areas offering faster relief to patients compared with oral medications.
In 2023, the viral segment dominated the market and accounted for largest revenue share of 90.7% in 2023, owing to the higher transduction efficiency and frequently used in gene therapy as they offer effective gene transfer to target cell. Moreover, viral vectors offer the advantage of delivering vaccines directly to specific cells or tissues and can target to many cells.
The non-viral segment is expected to witness the fastest CAGR of 12.1% during the forecast period. Non-viral vector is regarded as safer process than viral vector as they are dependent on physical or chemical methods of delivering genetic materials into a cell.
In 2023, North America market dominated the drug and gene delivery devices market with a revenue share of 54.0%, owing to rising number of people suffering from chronic diseases. According to centers for disease control and prevention (CDC), out of an estimated 129 million people in U.S. have at least 1 major chronic disease like cancer, diabetes, heart disease, obesity. Moreover, five of the top 10 deaths in the U.S. are strongly associated with preventable and treatable chronic diseases. The increasing awareness among people regarding the availability of various life-saving drug delivery devices is contributing to the growth of gene and drug delivery devices in North America.
In 2023, the U.S. drug and gene delivery devices market emerged as a frontrunner, capturing a significant market revenue of 259.6 million, owing to increasing prevalence of chronic diseases, the rising geriatric population and the rapid advancements in healthcare technologies. Furthermore, the support from regional government and well-established regulatory framework boosts the development of new gene and drug therapies.
The Europe drug and gene delivery devices market held a significant market share in 2023. The growth can be attributed to rise in prevalence of chronic disease, advancement in medical technologies and increase in healthcare expenditure. Europe holds a leading position internationally owing to the development of effective and safe gene therapy procedures. Moreover, the investments in research and development have led to the new findings in drug and gene delivery devices market in region.
The Germany drug and gene delivery devices market held the largest market share in the Europe region in 2023, driven by the increasing number of pharmaceuticals companies developing new cell therapies.
The UK drug and gene delivery devices market is expected to grow at the fastest CAGR during the forecast period. The major factor contributing to the UK drug and gene delivery devices market is the increasing expenditure in healthcare, adoption of highly-tech medical devices and rising prevalence of chronic disease. According to a study, 9.1 million people in England are projected to be living with major illness by 2040.
The drug and gene delivery devices market in Asia Pacific is projected to witness growth during the forecast period. The growth can be attributed to the increasing prevalence of chronic diseases such as heart disease, diabetes and cancer owing to the changing lifestyle, increase in consumption of alcohols and cigarettes.
The China drug and gene delivery devices market held the largest market share in 2023 owing to the improved and advanced healthcare infrastructure. China has the one of the fastest growing ageing populations in the world who are more prone to several chronic diseases. Moreover, the presence of large pharmaceutical companies in China is fueling the market.
The India drug and gene delivery devices market is expected to witness a significant growth during the forecast period, owing to the increasing prevalence of chronic disease and rising expenditure in healthcare. According to health insurance stats in India, 1 in 4 deaths is due to hypertension, 1 in 5 adults have diabetes and 1 in 4 deaths is due to cardiovascular disease. Furthermore, the rising awareness among people and increasing spending on health and health insurance is boosting the drug and gene delivery devices market in India.
Some of the key companies in the drug and gene delivery devices market include, Uniqure N.V.; Shanghai Sunway Biotech Co., Ltd; Pfizer, Inc.; Johnson and Johnson.
UniQure NV develops adeno-associated virus (AAV) based gene therapies with the help of its gene technology platform and offers treatments to patients suffering with severe genetic disorders.
Epeius Biotechnologies Corporation develops anti-cancer agents that eliminate metastatic disease.
The following are the leading companies in the drug and gene delivery devices market. These companies collectively hold the largest market share and dictate industry trends.
In February 2024, UT Southwestern collaborated with Pfizer to develop enhanced RNA delivery technologies. The collaboration is expected to advance the understanding of genetic medicine, expand AI design methodologies, thereby new delivery technologies developments for the creation of potential therapies.
Report Attribute |
Details |
Market size value in 2024 |
USD 725.30 million |
Revenue forecast in 2030 |
USD 1.22 billion |
Growth Rate |
CAGR of 9.0% from 2024 to 2030 |
Base year for estimation |
2023 |
Historical data |
2018 - 2022 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Route of administration, vector, region |
Regional scope |
North America, Europe, Asia Pacific, Latin America, MEA |
Country scope |
U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, Japan, China, India, Australia, South Korea, Thailand, Brazil, Argentina, South Africa, Saudi Arabia, UAE, Kuwait. |
Key companies profiled |
Uniqure N.V.,; SiBiono GeneTech Co.; Epeius Biotechnologies Corporation; Shanghai Sunway Biotech Co., Ltd; Pfizer, Inc.; F. Hoffmann-La Roche Ltd.; Johnson and Johnson; Novartis AG; Bayer AG; Becton, Dickinson and Company; |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the drug and gene delivery devices market report based on route of administration, vector and region.
Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Oral
Inhalation
Transdermal
Injectable
Ocular
Nasal
Topical
Vector Outlook (Revenue, USD Million, 2018 - 2030)
Viral
Non-viral
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."